Foghorn Therapeutics(FHTX)
$2.07+0.02 (+0.98%)
FHTX
Foghorn Therapeutics stock drug pipeline
$2.07
At close:+0.02 (+0.98%)
Want to see FHTX full AI Analyst Report?
Foghorn Therapeutics (FHTX) Drug Pipeline
445 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Fhd-609 | Advanced Synovial Sarcoma | Phase I | Terminated | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Jun 26, 2021 | ― |
| Decitabine, Fhd-286, Low Dose Cytarabine | Refractory Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia, Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | Phase I | Active Not Recruiting | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | May 13, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Fhd-609 | Phase I | Advanced Synovial Sarcoma | Terminated | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Jun 26, 2021 | ― |
| Decitabine, Fhd-286, Low Dose Cytarabine | Phase I | Refractory Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia, Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | Active Not Recruiting | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | May 13, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Foghorn Therapeutics, Inc. (FHTX) have in its pipeline
Foghorn Therapeutics FHTX is currently developing the following drugs: Fhd-609, Decitabine, Fhd-286, Low Dose Cytarabine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

